10.18565/cardio.2014.7.53-59 28
Study Design and Population The trial enrolled 445 participants across three groups in a 1:1:1 randomization: Retatrutide 9mg group: 148 participants Retatrutide 12mg group: 149 participants Placebo group: 148 participants Participants had an average baseline weight of 112.7 kg (248.5 lbs) and a mean BMI of 40.4 kg/m
This compounded blend is ideal for individuals seeking: Administered as a subcutaneous injection, typically once weekly , under the guidance of a Hush Medical Spa provider
This one rebuilds the surface (GHK-Cu) and protects the cellular machinery underneath (Epitalon), visible results and longevity support from a single daily injection
Otherwise, patients may not know what dosage to take and end up over-medicating themselves
Be aware that dose changes, including increases, are the most common trigger for this side effect